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column® treatment of moderate severe UC and CD patients is
associated with cost offsets for surgery, hospitalizations, outpa-
tient care and drugs and an increase of QALYs. The cost-effec-
tiveness ratios remain within the acceptable range for treatments
to be recommended for use in Sweden.
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OBJECTIVES: To assess cost-effectiveness of esomeprazole 
40mg (SEK 14.68 / tablet: EUR 1 = SEK 9.27, June 15, 2005)
once daily (od) versus omeprazole 20mgod at the lowest avail-
able generic drug price (SEK 4.32 / tablet) in the acute treatment
of reﬂux esophagitis (RE) in Sweden. METHODS: A decision
analysis model was used considering pooled effectiveness data
from comparative clinical studies and patient management
assumptions based on expert opinions. Results were analysed
using an 8-week time horizon and reported separately including
work productivity costs or direct medical costs (drugs, physician
contacts, investigations) only. Utility values associated with
having healed RE (0.84) or unhealed RE (0.69) were derived
from a study using the rating scale method in patients with
gastro-esophageal reﬂux disease (GERD). Estimates of GERD-
related work productivity loss (absence from work and reduced
productivity while at work) were derived from observed differ-
ences in productivity before and after treatment in another study.
A probabilistic sensitivity analysis (PSA) on direct medical 
costs was used to assess robustness of results, along with addi-
tional analyses extending the time horizon beyond 8 weeks. An
acceptable threshold of SEK 500,000 per quality-adjusted life
year (QALY) gained was used in the PSA. RESULTS: When
including direct medical costs only, the analysis resulted in mean
additional costs of around SEK 200,000 per QALY gained by
using the more effective acid inhibitory treatment strategy
(esomeprazole). The PSA on the probability of esomeprazole
treatment being below a SEK 500,000 per QALY gained thresh-
old supported robustness of a conclusion that esomeprazole
treatment is cost-effective. When work productivity costs were
included, results indicated that the esomeprazole strategy is 
cost-neutral. Extending the time horizon resulted in further cost-
effectiveness advantages for esomeprazole. CONCLUSION:
Esomeprazole 40mgod is cost-effective compared with generic
omeprazole 20mgod in the acute treatment of reﬂux esophagi-
tis in Sweden.
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OBJECTIVES: To determine the relative cost effectiveness of
proton pump inhibitor (PPI) based triple therapy regimens for
the eradication of Helicobacter pylori (H. pylori) in the primary
care setting in Ireland. METHODS: Using decision tree analysis
the expected cost for each H. pylori eradication strategy was
determined from the cost of each treatment option multiplied by
the probability of that option occurring. Only direct costs relat-
ing to the primary care setting such as GP consultation and 
medication costs, extracted from the Monthly Index of Medical
Specialties 2003, were included. Probabilities were obtained
using the GMS prescribing database where all patients who
received amoxycillin, clarithromycin and a PPI in the ERHA
region in 2002 were followed for one year. A broad range of clin-
ical and cost inputs was investigated by sensitivity analysis.
RESULTS: The main outcome measure was the cost per asymp-
tomatic patient for each therapeutic strategy. Depending on the
regimen adopted, 40.8% to 46.1% of patients did not require
any further medication in the year following H. pylori eradica-
tion treatment. The strategy of rabeprazole, amoxycillin and
clarithromycin was the most cost effective option with a cost of
€466 per asymptomatic patient. Two way sensitivity analysis
indicated that the cost of rabeprazole triple therapy and the dura-
tion of rabeprazole maintenance therapy would each have to
increase by 30% before this strategy ceased to be the most cost
effective option. CONCLUSION: This study indicates that the
triple therapy regimen of rabeprazole, amoxycillin and clar-
ithromycin is the most cost effective of the therapeutic strategies
examined for the treatment of H. pylori infection in the com-
munity setting in Ireland.
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OBJECTIVE: To determine the differences in indirect costs and
quality of life between persons affected by Crohn’s Disease (CD)
and those affected by Ulcerative Colitis (UC) as part of a cost of
IBD study in Germany. METHODS: Members of the German
Inﬂammatory Bowel Disease (IBD) Association (DCCV) were
recruited by post to prospectively document their IBD-associated
costs (sick leave, disability pensions, and medical resource use)
in a cost diary over 4 weeks. General demographic information
and IBD history were also reported. Health-Related Quality of
Life (hrQoL) was determined using the EuroQol EQ5-D. Indi-
rect costs were calculated according to national sources using the
human capital approach. RESULTS: Cost diaries were returned
by 483 persons (CD: 241; UC: 242) whose mean age was 42
years and average disease duration 13 years. Productivity losses
were reported by CD (14%) and UC (15%) subjects and average
sick leave was similar (CD: 1.2 days; UC: 1.5 days). However,
more CD (19%) than UC (7%) patients received a disability
pension. The mean 4-week indirect costs for CD were €266
(95%CI: 100, 433) higher than for UC (p < 0.002). The mean
hrQoL of CD subjects according to EuroQol VAS scores was 5
points lower (95%CI: -8.3, -1.7) than for UC subjects (p <
0.004). CONCLUSIONS: In Germany, indirect costs of CD are
signiﬁcantly higher than those of UC and hrQoL of CD patients
is signiﬁcantly lower than of UC patients. For CD, factors
decreasing occupational disability would decrease costs and since
hrQoL is also determined by the ability to work productively,
may improve hrQoL. Factors affecting indirect costs, which
account for a large part of the costs of IBD, can have a large
impact on the overall costs. Furthermore, these ﬁndings indicate
that determinants of costs must be searched for and evaluated
separately for each disease.
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Rationale: Acute-on-chronic liver failure (ACLF) is a life-threat-
ening acute deterioration of a chronic liver disease with severe
jaundice and hepatic encephalopathy. There are no cost-of-illness
studies of the treatment of ACLF available. OBJECTIVES: To
determine the average cost of the treatment of ACLF and testing
of important clinical variables for their predictive value for the
treatment costs. Methodology: Based on the sample of all ACLF-
patients treated in a large German university hospital from 1999
to 2001 detailed cost of the initial hospital stay and a three year
follow-up period were determined. Data on resource use were
collected from hospitals patient ﬁles and internal statistics as well
as by standardized interviews and questionnaires to patients and
their treating GPs. Costs were calculated from a German health
care system perspective and standardized to EUR of 2002. Addi-
tionally to age, sex, aetiology and severity of liver failure another
15 relevant clinical variables were tested in single and multiple
regression analyses. RESULTS: A total of 69 patients with ACLF
could be identiﬁed. Mean costs per patient were €21,058;
€11,259 for the initial hospital stay and €9799 for the following
3 years. Biggest inﬂuence had treatment with artiﬁcial liver
support systems. Other signiﬁcant variables in the model were
renal dialysis and aetiology of the disease. All other variables
including sex, age, severity of ACLF and several laboratory para-
meter did not have a relevant inﬂuence on the costs. CONCLU-
SION: A straight and relatively simple method to identify the
main cost drivers for ACLF-treatment is presented. The results
are absolutely plausible from a clinical point of view and stable
to variation of the model structure. The results underline the
necessity to differentiate the reimbursement systems for hepa-
torenal syndrome or additional renal failure, artiﬁcial liver
support and the aetiology of ACLF.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD) is a
chronic, potentially debilitating condition characterized by 
frequent and persistent heartburn and acid regurgitation. The
objective of this study was to evaluate the effects of GERD on
work productivity, deﬁned as productivity loss due to absen-
teeism and reduced effectiveness while working (presenteeism).
METHODS: Studies quantifying health-related work productiv-
ity loss in individuals with GERD were identiﬁed using system-
atic literature searches. Work productivity loss due to
absenteeism was expressed as number of hours lost, and as the
percentage of the total employed time. Presenteeism was
expressed as number of hours lost, and as the percentage reduced
effectiveness while at work. Overall productivity losses (absen-
teeism plus presenteeism) were valued in US dollars using the
human capital method. RESULTS: Six publications covering ﬁve
studies conducted in the USA, Canada and Sweden were eligible
for inclusion. Reported work productivity losses among individ-
uals with GERD ranged from 6% to 40%, and were primarily
due to presenteeism (6%–40%) rather than absenteeism
(<1%–6%). Work productivity impairment correlated with
symptom severity, and was greatest in patients experiencing sleep
disturbance due to GERD symptoms and lowest in GERD
patients taking prescription medication. Acid-suppressive
therapy improved productivity at work, especially in individuals
with GERD-associated sleep disturbances. The mean overall pro-
ductivity losses per employee with GERD were estimated at
$51–$396 per week, assuming a 40-hour working week and
average US wages. CONCLUSION: GERD has a substantial eco-
nomic impact, primarily by impairing employee productivity
while at work. The burden of lost productivity may be reduced
by acid-suppressive therapy, especially in employees with night-
time symptoms of GERD.
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OBJECTIVES: To compare the accuracy of two absenteeism
measures (days missed and hours missed) for inclusion in 
economic evaluations of IBS. METHODS: 135 IBS patients
recruited from ﬁve US gastroenterology practices completed the
Work Productivity and Activity Impairment questionnaire for
IBS (WPAI : IBS), which assesses absenteeism with hours missed,
and also completed questions about days and partial days
missed. Days and partial days were considered to be the equiv-
alent of 8 hours and 4 hours, respectively. RESULTS: 125
patients were employed, had complete data, and were included
in the analysis. A total of 6.4% of patients reported missing days
from work due to IBS in the prior 7 days, with an overall absen-
teeism rate of 1.8%; 28.0% of patients reported missing hours,
with an overall absenteeism rate of 4.3%. Among those report-
ing hours missed, 42.9% missed less than 3 hours, 34.3% missed
3 to 5 hours, and 22.9% missed 8 to 30 hours. When days missed
was used to measure absenteeism, 77.2% of patients missing
hours and 60.7% of time missed due to IBS were not counted;
when hours missed was reported, all patients reporting days
missed were counted. Combining partial days missed with days
missed increased the correspondence between those reporting
days and hours missed, but considerably overstated absenteeism
because partial-day absences were often less than 4 hours. Pre-
vious validation of the WPAI : IBS hours missed measure of
absenteeism relative to measures of disease severity, verbatim
responses and retrospective diaries, corroborates the inaccuracy
of the days missed measure. CONCLUSIONS: Hours missed
from work, not days missed, is a more accurate measure for cap-
turing the partial-day absences characteristic of IBS patients.
Other chronic disorders like IBS may exhibit a similar pattern of
widespread absences of short duration, and that absenteeism
may go undetected when days missed is the measure of 
absenteeism.
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OBJECTIVES: In Brazil it is estimated that there are more than
3 million patients chronically infected with HCV, making this
disease a major public health problem. HCVI leads to chronic
liver disease states such as cirrhosis and the need for transplan-
tation. There is little published data on the cost of HCVI in
Brazil. The aim of this study is to investigate medical resource
use and direct treatment costs for each state of HCV infection
from the perspective of the private medicine payers in Brazil.
METHODS: Three Delphi panels were performed, one with
hepatologists, one with intensivists and another with oncologists
in order to delineate practice patterns and to obtain resource uti-
lization for routine treatment and monitoring, adverse event
management and other clinical parameters representative 
